VDAC1 is essential for neurite maintenance and the inhibition of its oligomerization protects spinal cord from demyelination and facilitates locomotor function recovery after spinal cord injury

Imagem de Miniatura
Arquivos
art_PASCHON_VDAC1_is_essential_for_neurite_maintenance_and_the_2019.PDF (4.96 MB)
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Autores
PASCHON, Vera
MORENA, Beatriz Cintra
CORREIA, Felipe Fernandes
BELTRAME, Giovanna Rossi
KIHARA, Alexandre Hiroaki
Citação
SCIENTIFIC REPORTS, v.9, article ID 14063, 14p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
During the progression of the neurodegenerative process, mitochondria participates in several intercellular signaling pathways. Voltage-dependent anion-selective channel 1 (VDAC1) is a mitochondrial porin involved in the cellular metabolism and apoptosis intrinsic pathway in many neuropathological processes. In spinal cord injury (SCI), after the primary cell death, a secondary response that comprises the release of pro-inflammatory molecules triggers apoptosis, inflammation, and demyelination, often leading to the loss of motor functions. Here, we investigated the functional role of VDAC1 in the neurodegeneration triggered by SCI. We first determined that in vitro targeted ablation of VDAC1 by specific morpholino antisense nucleotides (MOs) clearly promotes neurite retraction, whereas a pharmacological blocker of VDAC1 oligomerization (4, 4'-diisothiocyanatostilbene-2, 2'-disulfonic acid, DIDS), does not cause this effect. We next determined that, after SCI, VDAC1 undergoes conformational changes, including oligomerization and N-terminal exposition, which are important steps in the triggering of apoptotic signaling. Considering this, we investigated the effects of DIDS in vivo application after SCI. Interestingly, blockade of VDAC1 oligomerization decreases the number of apoptotic cells without interfering in the neuroinflammatory response. DIDS attenuates the massive oligodendrocyte cell death, subserving undisputable motor function recovery. Taken together, our results suggest that the prevention of VDAC1 oligomerization might be beneficial for the clinical treatment of SCI.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/34060
Referências
  1. Agrawal SK, 1996, J NEUROSCI, V16, P545
  2. Almad A, 2011, NEUROTHERAPEUTICS, V8, P262, DOI 10.1007/s13311-011-0033-5
  3. Amphoux-Fazekas T, 1998, MOL CELL ENDOCRINOL, V141, P129, DOI 10.1016/S0303-7207(98)00100-2
  4. Aouacheria A, 2017, NEUROCHEM INT, V109, P141, DOI 10.1016/j.neuint.2017.04.009
  5. Arbel N, 2012, J BIOL CHEM, V287, P23152, DOI 10.1074/jbc.M112.345918
  6. Arbel N, 2010, J BIOL CHEM, V285, P6053, DOI 10.1074/jbc.M109.082990
  7. Arif T, 2017, MOL THER-NUCL ACIDS, V8, P493, DOI 10.1016/j.omtn.2017.08.008
  8. ARMSTRONG DM, 1986, PROG NEUROBIOL, V26, P273, DOI 10.1016/0301-0082(86)90021-3
  9. Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465
  10. Banati RB, 2004, J NEUROCYTOL, V33, P535, DOI 10.1007/s11068-004-0515-7
  11. Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343
  12. Bayrhuber M, 2008, P NATL ACAD SCI USA, V105, P15370, DOI 10.1073/pnas.0808115105
  13. Beattie MS, 2002, PROG BRAIN RES, V137, P37
  14. Benitez-Rangel E, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.37
  15. Bernstein BW, 2003, J NEUROSCI, V23, P1
  16. CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803
  17. Camara AKS, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00460
  18. Caterino M, 2017, MOL BIOSYST, V13, P2466, DOI 10.1039/c7mb00434f
  19. COLLINS WF, 1983, PARAPLEGIA, V21, P204, DOI 10.1038/sc.1983.34
  20. COOK RD, 1973, BRAIN RES, V61, P191, DOI 10.1016/0006-8993(73)90527-1
  21. Cristante AF, 2012, CLINICS, V67, P1219, DOI 10.6061/clinics/2012(10)16
  22. de Chaumont F, 2012, NAT METHODS, V9, P690, DOI [10.1038/NMETH.2075, 10.1038/nmeth.2075]
  23. De Pinto Vito, 2003, Ital J Biochem, V52, P17
  24. De Pinto V, 2010, FEBS LETT, V584, P1793, DOI 10.1016/j.febslet.2010.02.049
  25. De Stefani D, 2012, CELL DEATH DIFFER, V19, P267, DOI 10.1038/cdd.2011.92
  26. DePaul MA, 2015, SCI REP-UK, V5, DOI 10.1038/srep16795
  27. Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
  28. Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911
  29. Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004
  30. Ghosh T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001170
  31. GRIFFITHS IR, 1983, J NEUROL SCI, V58, P335, DOI 10.1016/0022-510X(83)90093-X
  32. Hall ED, 1989, J NEUROTRAUM, V6, P227, DOI 10.1089/neu.1989.6.227
  33. Huang H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.419
  34. Israelson A, 2010, NEURON, V67, P575, DOI 10.1016/j.neuron.2010.07.019
  35. Jacobs D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40979-8
  36. Keinan N, 2010, MOL CELL BIOL, V30, P5698, DOI 10.1128/MCB.00165-10
  37. Khosravi-Far R, 2004, CANCER BIOL THER, V3, P1051, DOI 10.4161/cbt.3.11.1173
  38. Kigerl KA, 2009, CURR TOP MICROBIOL, V336, P121, DOI 10.1007/978-3-642-00549-7_7
  39. Krumschnabel G, 2007, APOPTOSIS, V12, P1755, DOI 10.1007/s10495-007-0103-7
  40. Kuroiwa M, 2014, EUR J NEUROSCI, V40, P3120, DOI 10.1111/ejn.12647
  41. Langlois Sebastien D, 2010, J Vis Exp, DOI 10.3791/1773
  42. Li HY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167908
  43. Magri A, 2016, SCI REP-UK, V6, DOI 10.1038/srep34802
  44. Maidana DE, 2015, INVEST OPHTH VIS SCI, V56, P6701, DOI 10.1167/iovs.15-17599
  45. Manczak M, 2013, J ALZHEIMERS DIS, V37, P679, DOI 10.3233/JAD-130761
  46. Mannella CA, 1997, J BIOENERG BIOMEMBR, V29, P525, DOI 10.1023/A:1022489832594
  47. Marginedas-Freixa I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29885-7
  48. Martin LJ, 2009, EXP NEUROL, V218, P333, DOI 10.1016/j.expneurol.2009.02.015
  49. MCENERY MW, 1993, J BIOL CHEM, V268, P23289
  50. Miller AD, 2012, J MED PRIMATOL, V41, P202, DOI 10.1111/j.1600-0684.2012.00542.x
  51. Morris R, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00005
  52. Morrison H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13581-z
  53. Norenberg MD, 2004, J NEUROTRAUM, V21, P429, DOI 10.1089/089771504323004575
  54. Okada SF, 2004, J GEN PHYSIOL, V124, P513, DOI 10.1085/jgp.200409154
  55. Paschon V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060486
  56. Paschon V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045449
  57. Pavlov E, 2005, BBA-BIOENERGETICS, V1710, P96, DOI 10.1016/j.bbabio.2005.09.006
  58. PFALLER R, 1985, J BIOL CHEM, V260, P8188
  59. Raghavan A, 2012, BBA-BIOMEMBRANES, V1818, P1477, DOI 10.1016/j.bbamem.2011.10.019
  60. Saminathan A, 2013, J PERIODONTAL RES, V48, P790, DOI 10.1111/jre.12072
  61. SANDLER AN, 1976, J NEUROSURG, V45, P660, DOI 10.3171/jns.1976.45.6.0660
  62. Schwartz G, 2002, PROG BRAIN RES, V137, P177
  63. Shoshan-Barmatz V, 2006, CURR PHARM DESIGN, V12, P2249, DOI 10.2174/138161206777585111
  64. Shoshan-Barmatz V, 2012, MITOCHONDRION, V12, P24, DOI 10.1016/j.mito.2011.04.001
  65. Shoshan-Barmatz V, 2010, BBA-BIOENERGETICS, V1797, P1281, DOI 10.1016/j.bbabio.2010.03.003
  66. Shoshan-Barmatz V, 2010, MOL ASPECTS MED, V31, P227, DOI 10.1016/j.mam.2010.03.002
  67. Shoshan-Barmatzt V, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00164
  68. ShoshanBarmatz V, 1996, FEBS LETT, V386, P205, DOI 10.1016/0014-5793(96)00442-5
  69. Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326
  70. Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5
  71. TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015
  72. THINNES FP, 1994, BIOL CHEM H-S, V375, P315, DOI 10.1515/bchm3.1994.375.5.315
  73. Tomaskova Z, 2007, J BIOENERG BIOMEMBR, V39, P301, DOI 10.1007/s10863-007-9090-1
  74. van Niekerk EA, 2016, MOL CELL PROTEOMICS, V15, P394, DOI 10.1074/mcp.R115.053751
  75. Wang HF, 2017, NEURAL REGEN RES, V12, P1724, DOI 10.4103/1673-5374.217354
  76. Wang XD, 2001, GENE DEV, V15, P2922
  77. Wilson MC, 2009, J BIOL CHEM, V284, P20011, DOI 10.1074/jbc.M109.014217
  78. Wohlrab D, 2000, EXP DERMATOL, V9, P219, DOI 10.1034/j.1600-0625.2000.009003219.x
  79. Xiang NL, 2016, SCI REP-UK, V6, DOI 10.1038/srep27583
  80. Zalk R, 2005, BIOCHEM J, V386, P73, DOI 10.1042/BJ200041356

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOT
Artigos e Materiais de Revistas Científicas - HC/IOT
Artigos e Materiais de Revistas Científicas - LIM/41